Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.44 |
| ▸ | MTOR | P42345 | 3/20 | 0.44 |
| ▸ | BCHE | P06276 | 3/20 | 0.44 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL424853 | 0.83 | PIKFYVE (0.64) | HPGDLMNAKDM4EPIK3CAMTOR | |
| SCHEMBL424854 | 0.83 | PIKFYVE (0.64) | HPGDLMNAKDM4EPIK3CAMTOR | |
| SCHEMBL425312 | 0.82 | PIK3R1 (0.51) | MERTKALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL11863510 | 0.72 | LMNA (0.53) | MERTKALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL11863517 | 0.71 | ALDH1A1 (0.52) | MERTKALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL425523 | 0.69 | MTOR (0.70) | ALDH1A1HPGDSMN1; SMN2LMNAKDM4E | |
| SCHEMBL11739337 | 0.68 | ATM (0.70) | ALDH1A1HPGDSMN1; SMN2LMNAKDM4E | |
| SCHEMBL4137879 | 0.68 | SMN1; SMN2 (0.54) | ALDH1A1HPGDSMN1; SMN2LMNAKDM4E | |
| SCHEMBL14412719 | 0.68 | PIK3CA (0.55) | ALDH1A1HPGDLMNAKDM4EMAPK1 | |
| SCHEMBL21054953 | 0.67 | PIKFYVE (0.63) | ALDH1A1HPGDLMNAKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | MERTK 2605/4885ALDH1A1 1903/4885HPGD 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.